Objectives: The time that drugs for moderate-to-severe psoriasis take to see a clinically meaningful improvement (TOA) is one of the most important attributes of treatment success. This study synthesizes TOA data from previously reviewed drugs and adds clinical data for tidrakizumab and certolizumab pegol for comparison. Methods: We reviewed published and presented efficacy data regarding TOA, which was defined as the time at which 25% of the sample population reached Psoriasis Area and Severity Index (PASI) 75 or the time at which the sample population reached a mean PASI 50. Results: Antipsoriatic drugs obtained clinically meaningful outcomes within 1.8-25.4 w, and brodalumab had the fastest TOA for both outcome measures. Conclusion: Brodalumab may continue to have the most rapid onset of action of available antipsoriatic therapies. J Drugs Dermatol. 2019;18(3):229-233.